Wealthfront Advisers LLC Makes New Investment in West Pharmaceutical Services, Inc. $WST

Wealthfront Advisers LLC purchased a new position in West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 6,440 shares of the medical instruments supplier’s stock, valued at approximately $2,312,000.

A number of other institutional investors have also modified their holdings of WST. Avalon Trust Co acquired a new stake in West Pharmaceutical Services during the second quarter worth about $28,000. Elyxium Wealth LLC bought a new position in West Pharmaceutical Services in the fourth quarter worth about $25,000. Bayban acquired a new position in West Pharmaceutical Services in the fourth quarter valued at approximately $27,000. Private Trust Co. NA grew its holdings in shares of West Pharmaceutical Services by 156.4% during the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 61 shares during the last quarter. Finally, DV Equities LLC acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter worth approximately $28,000. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Up 0.5%

WST opened at $354.53 on Friday. The stock’s 50 day moving average price is $348.11 and its 200 day moving average price is $299.38. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The stock has a market cap of $24.95 billion, a P/E ratio of 45.39, a P/E/G ratio of 2.47 and a beta of 1.15. West Pharmaceutical Services, Inc. has a 12 month low of $223.83 and a 12 month high of $386.00.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.08 by $0.29. The company had revenue of $872.30 million during the quarter, compared to analysts’ expectations of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, research analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were paid a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.27%.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Stephens reissued an “overweight” rating and issued a $360.00 price target on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Evercore reaffirmed an “outperform” rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. TD Cowen restated a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Finally, Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.